Login
$REGN
$953.36 +$0.96 (0.1%) After hours

$REGN 8-K SEC Filings

Filed On Filing
30 Oct 2026 8-K: Results of Operations and Financial Condition

Tarrytown, New York (October 30, 2026) -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the third quarter of 2026 and provided a business update.

06 Oct 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more

On October 1, 2026, Regeneron Pharmaceuticals, Inc., a New York corporation (“Regeneron” or the “Company”), Sanofi Biotechnology SAS, a société par actions simplifée organized under the laws of France (“Sanofi Biotechnology”), and Sanofi...

30 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

Plan: Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan

30 Jul 2026 8-K: Results of Operations and Financial Condition

Tarrytown, New York (July 30, 2026) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2026 and provided a business update.

06 Jul 2026 8-K: Results of Operations and Financial Condition

Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the s...

17 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

At the 2026 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) held on June 12, 2026, Regeneron’s shareholders voted on the matters set forth below.

29 Apr 2026 8-K: Results of Operations and Financial Condition

Tarrytown, New York (April 29, 2026) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2026 and provided a business update.

08 Apr 2026 8-K: Results of Operations and Financial Condition

Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the f...

30 Jan 2026 8-K: Results of Operations and Financial Condition

Tarrytown, New York (January 30, 2026) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2025 and provided a business update.

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

J a n u a r y 1 2 , 2 0 2 6 J.P. Morgan Healthcare Conference This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially.

28 Oct 2025 8-K: Results of Operations and Financial Condition

Tarrytown, New York (October 28, 2025) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2025 and provided a business update.

06 Oct 2025 8-K: Results of Operations and Financial Condition

Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the t...

01 Aug 2025 8-K: Results of Operations and Financial Condition

Tarrytown, New York (August 1, 2025) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2025 and provided a business update.

18 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

At the 2025 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) held on June 13, 2025, Regeneron’s shareholders voted on the matters set forth below.

29 Apr 2025 8-K: Results of Operations and Financial Condition

Tarrytown, New York (April 29, 2025) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2025 and provided a business update.

04 Feb 2025 8-K: Results of Operations and Financial Condition; Other Events

Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion

13 Jan 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference

31 Oct 2024 8-K: Results of Operations and Financial Condition

Tarrytown, New York (October 31, 2024) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update.

07 Oct 2024 8-K: Results of Operations and Financial Condition

Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the t...

01 Aug 2024 8-K: Results of Operations and Financial Condition

Tarrytown, New York (August 1, 2024) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2024 and provided a business update.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support